Type 1 Diabetes Patient Produces Own Insulin After Genetically Modified Cell Transplant

The New England Journal of Medicine posted the findings on its official account, reporting that a single patient received what are called allogeneic islets — insulin-producing clusters of cells taken from a donor, then genetically modified — and showed sustained beta-cell function throughout the study period. Beta cells are the cells in the pancreas that make insulin, and in type 1 diabetes the body’s immune system destroys them.

What makes this case stand out is the absence of immunosuppression. Normally, anyone receiving donor tissue must take powerful drugs for life to stop their immune system attacking the foreign cells. According to the journal, this patient showed no immune response against the transplanted cells across the 14-month follow-up period.

The journal described these as “results obtained through 14 months” — meaning this is early-stage data from one patient, not a large clinical trial. No figures on wider patient numbers, success rates, or timelines for broader testing were included in the published findings.

Type 1 diabetes affects around 400,000 people in the UK, according to NHS estimates. Current treatment requires daily insulin injections or a pump, with no cure available through standard care.

Kent residents with questions about diabetes management or their own treatment should contact their GP or call NHS 111. For general information on type 1 diabetes, NHS England publishes guidance through its patient information services.